A turbulent year at the agency.
作者信息
Ratner Mark
出版信息
Nat Biotechnol. 2006 Feb;24(2):145-51. doi: 10.1038/nbt0206-145.
PMID:16465153
Abstract
摘要
相似文献
1
A turbulent year at the agency.
Nat Biotechnol. 2006 Feb;24(2):145-51. doi: 10.1038/nbt0206-145.
2
FDA embraces risk-management approach.
Nat Biotechnol. 2003 Oct;21(10):1120-1. doi: 10.1038/nbt877.
3
The big gap at the FDA.
Fortune. 2002 Jul 22;146(2):113-4, 116.
4
FDA appointee faces angry, demoralized staff.
Nat Biotechnol. 2002 Nov;20(11):1065. doi: 10.1038/nbt1102-1065a.
5
Muddied messages about FDA.
Nat Biotechnol. 2003 Jul;21(7):732-3. doi: 10.1038/nbt0703-732.
6
New office and new leader aim to streamline FDA cancer drug review process.
J Natl Cancer Inst. 2005 May 18;97(10):708-9. doi: 10.1093/jnci/97.10.708.
7
FDA and EMEA pool scientific advice.
Nat Biotechnol. 2004 Dec;22(12):1490-1. doi: 10.1038/nbt1204-1490.
8
Regulators scramble to tighten loopholes after heparin debacle.
Nat Biotechnol. 2008 May;26(5):477-8. doi: 10.1038/nbt0508-477.
9
Congress turns spotlight on US drug approval agency.
Nature. 1995 Apr 13;374(6523):582. doi: 10.1038/374582a0.
10
An overview from the Director of the Center for Food Safety and Applied Nutrition.
Food Drug Law J. 1999;54(1):43-48.
Zotero 插件